Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06805812CT.gov Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study | — | Recruiting | — | — | — |
NCT02586675CT.gov TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Male Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ribociclib (this asset) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P1 | CC · 47 |
| Adriamycin | National Cancer Institute (NCI) | P2 | BBB |
| Irinotecan | University of California, Irvine | P2 | BBB |
| Nivestim | University of Washington | P2 | BBB |
| Cyclophosphamide | Wake Forest University Health Sciences | P2 | BBB |
| Cediranib | University of Chicago | P2 | BB |
| Sargramostim | University of Washington | P2 | BB |
| Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute | P3 | BB |
| Tamoxifen | Jose Pablo Leone | P3 | BB |
+42 more in the Male Breast Carcinoma cohort
Other indications for Ribociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 73 |
| Breast Cancer | — | P4 | BB · 70 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ribociclib in Male Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ribociclib-male-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →